TOKYO — Japanese drugmaker Eisai is overhauling its U.S. operations as the company seeks ways to overcome the hurdles to wide adoption of its flagship Alzheimer’s disease treatment.
The company had laid off 121 employees as of April 1, including at its U.S. headquarters in the state of New Jersey. This accounts for 7% of Eisai’s workforce in the country.
